Will Imatinib Compromise Reproductive Capacity?

Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conven...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zamah, Alberuni M., Mauro, Michael J., Druker, Brian J., Oktay, Kutluk, Egorin, Merrill J., Cedars, Marcelle I., Rosen, Mitchell P.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2011
Matèries:
Leukemias
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228060/
https://ncbi.nlm.nih.gov/pubmed/21948652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0137
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars